Evidence map›Paper›PMID 36253447›Full record

ArticleOncogene2022

Retraction Note: CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus.

David Bernard, Juan F Martinez-Leal, Sian Rizzo, Dolores Martinez, David Hudson, Tapio Visakorpi, Gordon Peters, Amancio Carnero, David Beach, Jesus Gil

RetractedOpen access · bronzeAbstract readRetraction Notice
PubMed Publisher
In one paragraph

Article in Oncogene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

David BernardLaboratory of Molecular Virology, Faculty of Medicine, Free University of Brussels, Brussels, Belgium.
Juan F Martinez-LealExperimental Therapeutics Program, Centro Nacional de Investigaciones Oncológicas, Melchor Fernández Almagro 3, 28029, Madrid, Spain.
Sian RizzoProstate Stem Cell Laboratory, Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
Dolores MartinezWolfson Institute for Biomedical Research, University College London, Gower Street, London, WC1E 6BT, UK.
David HudsonProstate Stem Cell Laboratory, Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, UK.
Tapio VisakorpiCancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, University of Tampere, FIN-33014, Tampere, Finland.
Gordon PetersMolecular Oncology Laboratory, Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, WC2A 3PX, London, UK.
Amancio CarneroExperimental Therapeutics Program, Centro Nacional de Investigaciones Oncológicas, Melchor Fernández Almagro 3, 28029, Madrid, Spain.
David BeachCenter for Cutaneous Biology, Institute for Cell and Molecular Sciences, 2 Newark St, Whitechapel, E1 2AT, London, UK.
Jesus GilMolecular Oncology Laboratory, Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, WC2A 3PX, London, UK. jesus.gil@cancer.org.uk.
Institute of Cancer Research · GBSpanish National Cancer Research Centre · ESThe Honourable Society of Lincoln's Inn · GBTampere University Hospital · FIUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36253447
OpenAlexW4306411801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.